EPS growth is an important number as it indicates the future prospects of Apricus Biosciences. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but EPS has been 60.00% over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Apricus Biosciences is making for it’s investors or shareholders.
Apricus Biosciences is in the biotechnology industry and is part of the healthcare sector. The company CEO is Richard W. Pascoe. Apricus Biosciences Inc is a pharmaceutical company. It focuses on the development of product candidates in the areas of urology and rheumatology. The company has two product candidates currently in development including Vitaros and RayVa.
Previous Intraday Performance:
The APRI shares had a previous change of -2.08% which opened at 0.32 and closed at 0.31. It moved to an intraday high of 0.32 and a low of 0.31.
SeekingAlpha: Apricus Biosciences reports Q3 results
Historical Performance:
Over the last five trading days, APRI shares returned 1.97% and in the past 30 trading days it returned -2.27%. Over three months, it changed -1.29%. In one year it has changed -80.88% and within that year its 52-week high was 3.34 and its 52-week low was 0.25. APRI stock is 22.40% above its 52 Week Low.
Our calculations result in a 200 day moving average of 0.42 and a 50 day moving average of 0.32. Right now, APRI stock is trading -27.27% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Apricus Biosciences reports Q3 results
Liquidity:
The company has a market cap of $8.6m with 28.2m shares outstanding and a float of 15.7m shares. Trading volume was 138,163 shares and has experienced an average volume of 644,577 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Apricus Biosciences was 0.38 which ended on 31st of December 2017, which according to the previous close, that is a PE of 0.81.Historically, the PE high was 0.81 and the PE low was -0.59. APRI stock has set a new PE low record!
Below was the last reported quarterly earnings per share:
09-30-2018: -0.12
06-30-2018: -0.10
03-31-2018: -0.14
12-31-2017: -0.16
Indicators Also to Watch:
Based on the latest filings, there is 53.20% of insider ownership and 18.30% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 0.78
SeekingAlpha: Natural gas jumps as cold air descends on U.S. Midwest
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -188.50%, return on assets is -136.68% and price-to-book is 2.10.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: APRI, Apricus Biosciences, Biotechnology, Healthcare
